CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Enlivex Therapeutics Ltd.

ENLV
$11MMicro Cap

Next catalyst

Phase 2February 2027

Allocetra

Osteoarthritis, Knee

Get an email about ENLV's next catalysts

Track Enlivex Therapeutics (ENLV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 4 past

Phase 2Next

Allocetra Phase 2 Est. Readout

February 2027~Allocetra182

Estimated primary completion for Allocetra trial (NCT07580716) in Primary Knee Osteoarthritis. Topline data typically follows completion by weeks to months.

Source

How ENLV's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQFinance ServicesPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaTEL AVIV34 employees
Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Enlivex Therapeutics Ltd.'s drug pipeline?β†’

CatalystAlert tracks 2 drug candidates in Enlivex Therapeutics Ltd.'s (ENLV) pipeline across Phase 2. Its lead program is Allocetra (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Enlivex Therapeutics Ltd.'s next FDA catalyst?β†’

Enlivex Therapeutics Ltd.'s (ENLV) next tracked catalyst is a Phase 2 readout expected February 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track ENLV biotech catalysts?β†’

Add ENLV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Enlivex Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply